CD25^bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression

References

• Cornel AM, Mimpen IL, Nierkens S, Class MHC. I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers. 2020 2;12(7):Jul. doi:10.3390/cancers12071760.
   Web of Science ®Google Scholar
• Kundu S, Gurney M, O’Dwyer M. Generating natural killer cells for adoptive transfer: expanding horizons. Cytotherapy. 2021 Jan 8;23(7):559–8. doi:10.1016/j.jcyt.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Cozar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-Infiltrating natural killer cells. Cancer Discov. 2020 Dec 4;11(1):34–44. doi:10.1158/2159-8290.CD-20-0655.
   PubMed Web of Science ®Google Scholar
• Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007 Oct;27(4):635–646. doi:10.1016/j.immuni.2007.08.014.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Experimental Med. 2005 Oct 17;202(8):1075–1085. doi:10.1084/jem.20051511.
   PubMed Web of Science ®Google Scholar
• Littwitz-Salomon E, Akhmetzyanova I, Vallet C, Francois S, Dittmer U, Gibbert K. Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection. Retrovirology. 2015 Jul 30;12:66. doi:10.1186/s12977-015-0191-3.
   PubMed Web of Science ®Google Scholar
• Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med. 2013 Jun 3;210(6):1153–1165. doi:10.1084/jem.20122248.
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007 Dec 8;(12):1353–1362. doi:10.1038/ni1536.
   PubMed Web of Science ®Google Scholar
• Oberle N, Eberhardt N, Falk CS, Krammer PH, Suri-Payer E. Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immun. 2007 Sep 15;179(6):3578–3587. doi:10.4049/jimmunol.179.6.3578.
   PubMed Web of Science ®Google Scholar
• Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Masvidal L, Liang S, Murray S, Larsson O, et al. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood. 2016 Sep 15;128(11):1475–1489. doi:10.1182/blood-2016-02-698027.
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. J American Soc Blood Marrow Transp. 2014 Apr;20(4):463–473. doi:10.1016/j.bbmt.2014.01.006.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830. e14. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017 Dec;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, et al. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology. 2013 Mar 1;2(3):e23562. doi:10.4161/onci.23562.
   PubMed Web of Science ®Google Scholar
• Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, et al. 2017 Dec 7. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight.2(23). 10.1172/jci.insight.95128
   PubMed Web of Science ®Google Scholar
• Marcais A, Cherfils-Vicini J, Viant C, Degouve, S., Viel, S., Fenis, A. & Walzer, T. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014 Aug;15(8):749–757. doi:10.1038/ni.2936.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015 Oct 14;5:15179. doi:10.1038/srep15179.
   PubMed Web of Science ®Google Scholar
• Tao Q, Chen T, Tao L, Wang, H., Pan, Y., Xiong, S., & Zhai, Z. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. J immun. 2013 Nov-Dec;36(9):462–467. doi:10.1097/CJI.0000000000000001.
   Google Scholar
• Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012 Jan;14(1):91–103. doi:10.3109/14653249.2011.613931.
   PubMed Web of Science ®Google Scholar
• Martrus G, Kautz T, Lunemann S, Richert L, Glau L, Salzberger W, Goebels H, Langeneckert A, Hess L, Poch T, et al. Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. PloS one. 2017;12(8):e0182532. doi:10.1371/journal.pone.0182532.
   PubMed Web of Science ®Google Scholar
• Tao Y, Li YH, Piao HL, Zhou W-J, Zhang D, Fu Q, Wang S-C, Li D-J, Du M-R. CD56(bright)CD25+ NK cells are preferentially recruited to the maternal/fetal interface in early human pregnancy. Cell Mol Immunol. 2015 Jan;12(1):77–86. doi:10.1038/cmi.2014.26.
   PubMed Web of Science ®Google Scholar
• Mirjacic Martinovic K, Babovic N, Dzodic R, Jurisic V, Matkovic S, Konjevic G. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. J Transl Med. 2015 Apr 14;13:120. doi:10.1186/s12967-015-0479-z.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang Y, Neo SY, Shi H, Chen Y, Wagner AK, Larsson K, Tong L, Jakobsson P-J, Alici E, et al. Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD54 + NK cells. EMBO Rep. 2021 Mar 3;22(3):e51329. doi:10.15252/embr.202051329.
   PubMed Web of Science ®Google Scholar
• Yang Y, Neo SY, Chen Z, Cui W, Chen Y, Guo M, Wang Y, Xu H, Kurzay A, Alici E, et al. Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. J Clin Invest. 2020 Oct 1;130(10):5508–5522. doi:10.1172/JCI137585.
   PubMed Web of Science ®Google Scholar
• Bou-Tayeh B, Laletin V, Salem N, Just-Landi S, Fares J, Leblanc R, Balzano M, Kerdiles YM, Bidaut G, Hérault O, et al. Chronic IL-15 stimulation and impaired mTOR signaling and metabolism in natural killer cells during acute myeloid leukemia. Front Immunol. 2021;12:730970. doi:10.3389/fimmu.2021.730970.
   PubMed Web of Science ®Google Scholar
• Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, Geller MA, Tolar J, Blazar BR, Miller JS, et al. 2018 Feb 8. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight.3(3). 10.1172/jci.insight.96219
   PubMed Web of Science ®Google Scholar
• Han SJ, Kwon S, Kim KS. Challenges of applying multicellular tumor spheroids in preclinical phase. Cancer Cell Int. 2021 Mar 4;21(1):152. doi:10.1186/s12935-021-01853-8.
   PubMed Web of Science ®Google Scholar